On the other hand, our findings corroborate preclinical findings in BC, showing that eribulin resistance is promoted by the activation of the PI3K/AKT pathway [21], which holds a key role in maintaining the stemness of BC cells [22], and that the combination of eribulin with PI3K inhibition has synergistic antitumor effects by reducing the breast CSC population [30]. Here, AKT1 is linked to breast cancer.